Introduction
============

Schizophrenia is a severe psychiatric disorder. Antipsychotics are the first-line agents in the treatment of schizophrenia, but the clinical response is highly variable. Between 23% ([@B22]) and 47% ([@B115]) of patients met the criteria for treatment-resistant schizophrenia (TRS), although the definition has varied across different studies ([@B51]). In spite of more than 60 years of the widespread use of antipsychotics, TRS continues to present an enormous challenge ([@B96]; [@B68]). While altered dopaminergic function is the main feature of schizophrenia ([@B68]; [@B79]; [@B81]; [@B87]), patients with TRS might have distinct dopamine changes, such as lower dopamine synthesis capacity in the striatum ([@B61]), lower density of dopaminergic synapses in the caudate nucleus ([@B91]), and a decrease in the dopamine transporter protein expression ([@B89]), compared to patients who responded to antipsychotics. There is an urgent need to distinguish TRS from non-TRS using genetic or other markers ([@B96]; [@B68]; [@B40]) as early as possible, in order to provide the best possible treatment for an individual patient.

Catechol-*O*-methyltransferase (COMT) is an important enzyme that degrades catecholamines including dopamine. COMT regulates dopamine availability primarily in the prefrontal cortex (PFC), where the presence of dopamine transporters is scarce ([@B7]). Variants of the *COMT* gene have been extensively studied as risk factors for schizophrenia ([@B29]). Among various polymorphisms of the *COMT* gene, rs4680 and rs4818 significantly affect COMT activity and therefore prefrontal dopamine levels and function. The rs4680 (A \> G substitution) or Val108/158Met is the most common functional *COMT* polymorphism in which a G/A substitution results in valine (Val) to methionine (Met) replacement at codon 158 for membrane-bound (MB) COMT, and at codon 108 for the soluble (S) COMT. The Met (A) variant has been associated with a lower thermostability, fourfold lower functional enzyme activity ([@B67]), lower protein expression ([@B14]), and higher dopamine activity compared to Val (G) variant. Previously observed association between *COMT* rs4680 and schizophrenia ([@B29]; [@B42]) was not confirmed in a meta-analysis ([@B77]), or in a cohort with large number of ethnically homogeneous Caucasians in our previous study ([@B80]). Another frequently studied polymorphism of the *COMT* gene is a synonymous polymorphism rs4818, with a C/G substitution (Leu/Leu) at codon 86 of S-COMT or at codon 136 of MB-COMT ([@B94]). The G variant of the *COMT* rs4818 polymorphism is associated with greater COMT activity and therefore lower prefrontal dopamine activity ([@B94]). It has been reported that *COMT* rs4818 is responsible for the larger variation in the COMT activity than the *COMT* rs4680 polymorphism ([@B78]). Some studies demonstrated that *COMT* rs4818 polymorphism was not associated with schizophrenia ([@B15]; [@B71]); however, it is transmitted together with *COMT* rs4680 polymorphism in a haploblock ([@B48]). Contradictory findings exist for the association of *COMT* haplotypes and schizophrenia or its symptoms ([@B15]; [@B71]). Haplotype including *COMT* rs4818 G allele (with rs740603/G allele) was linked to negative symptoms of schizophrenia ([@B71]). However, no significant association of several functional *COMT* polymorphisms and haplotypes with schizophrenia or with psychopathological symptoms was found ([@B15]). Moreover, there were no differences between patients with and without TRS in the whole-blood gene expression of 13 genes, including *COMT* gene ([@B75]).

Despite a considerable amount of research on the association of *COMT* rs4680 variants with the response to antipsychotics ([@B52]), only four studies addressed this *COMT* polymorphism in relation to TRS ([@B55]; [@B10]; [@B113]; [@B90]). These studies yielded inconsistent results, had relatively small sample sizes and the data were not separately analyzed for males and females, although sex-specific associations with *COMT* rs4680 have been reported. For example, the overexpression of the rs4680 GG genotype was found in Spanish males with schizophrenia compared to general population, with no such differences in females ([@B49]). The presence of one or two A allele in the *COMT* rs4680 elevated the risk of violence in male, but not female patients with schizophrenia ([@B106]). On the other hand, when *COMT* rs4680 was investigated in Slovenian suicide victims, the AA genotype was more common in the group of control males than in males who committed suicide, and in the control males versus males who committed suicide with violent methods, while again no differences were observed among females ([@B84]). The interpretation of the influence of this *COMT* functional polymorphism in psychiatric disorders is therefore complicated by sex-, but also by ethnic-related differences in allele distributions. Whereas Caucasians had similar frequencies of the A and G alleles, the G allele was more common in Asian and other populations ([@B83]). In contrast to these findings, the A allele was associated with bipolar disorder in Asian but not in Caucasian subjects ([@B112]). Moreover, in the meta-analysis of case-control studies, the presence of the G allele of the *COMT* rs4680 was associated with schizophrenia in Caucasian, but not in Asian population, although the data were not analyzed by gender ([@B42]). In addition, only a few studies investigated *COMT* rs4818 polymorphism and the response to antipsychotics ([@B43]; [@B120]; [@B103]).

Since there is inconclusive or insufficient evidence on the association of *COMT* rs4680 and rs4818 polymorphisms with TRS, especially regarding gender and ethnic differences, the aim of this study was to evaluate genotypic and haplotypic association of the *COMT* rs4680 and rs4818 and TRS in ethnically homogeneous Caucasian subjects of both sexes. Our hypothesis was that patients with TRS have the overrepresentation of rs4680 A allele, as well as rs4818 C allele, compared to non-TRS patients, and that the observed associations with *COMT* are gender-specific.

Materials and Methods {#s1}
=====================

Subjects
--------

This cross-sectional study included 931 biologically unrelated Caucasian patients with schizophrenia, 585 males and 386 females, who gave their consent to participate and met the inclusion criteria, and were considered eligible. Subjects were recruited from the University Hospital Centre Zagreb, University Psychiatric Hospital Vrapce, Zagreb, and Neuropsychiatric Hospital Dr. Ivan Barbot, Popovaca, Croatia. Inclusion criteria were in- and out-patients aged 18--65 years, diagnosed with schizophrenia for at least 5 years. Diagnosis was confirmed using the Structured Clinical Interview (SCID; [@B37]) based on the DSM-IV criteria \[[@B3]\]. Exclusion criteria were intellectual disabilities, patients with first-episode psychosis and/or no previous treatment with antipsychotics, substance abuse and dependence in the previous three months, any comorbid severe somatic or neurological disorder and patients who had no available detailed medical records with complete psychiatric medication history. After inclusion, all patients underwent complete diagnostic evaluation. Clinical Global Impression-Severity (CGI-S) scale was used to assess the severity of patients' clinical condition ([@B45]). Patients were evaluated using structured interview for the Positive and Negative Syndrome Scale (PANSS) including the PANSS positive, PANSS negative and PANSS general psychopathology subscale ([@B59]). Schizophrenic patients were subdivided into 574 smokers (i.e., current smokers) and 354 non-smokers (i.e., never smokers and former smokers), whereas for three patients smoking status was not defined. Besides nicotine dependence, no other co-morbid substance abuse or dependence was present. All patients were Caucasians of Croatian origin. The patients were treated with different antipsychotic medication: olanzapine, either as monotherapy or antipsychotic combination (5--20 mg/day), clozapine (300--800 mg/day), risperidone (2--6 mg/day), fluphenazine (5--15 mg/day), haloperidol (4--15 mg/day), promazine (400--500 mg/day), alone or combined with benzodiazepines, i.e., diazepam (2--10 mg/day). Mean dose of antipsychotic medication, calculated into chlorpromazine equivalent doses, was 309.5 ± 263.5 mg/day (range 50--1600 mg/day). Although the concept of TRS is widely used, there is a lack of consensus how to define it. In our study, patients were classified in TRS or non-TRS group according to criteria proposed by [@B110], which refer to the failure of at least two antipsychotics, given at ≥600 mg chlorpromazine equivalents ([@B54]) for more than consecutive 6 weeks, assessed retrospectively. Out of 931 patients, 270 of them met the criteria for TRS and 661 were non-TRS patients. At the time of assessment, psychiatrists were not aware of the genetic test results. The study was approved by the Ethics Committees of the University Hospital Centre Zagreb, University Psychiatric Hospital Vrapce, and Neuropsychiatric Hospital Dr. Ivan Barbot, Popovaca, Croatia, and was carried out in accordance with the Helsinki declaration (1975), as revised in 1983. All patients have signed informed consent prior to study procedures.

Genotyping
----------

The *COMT* rs4680 (assay ID: C_25746809_50) and rs4818 (assay ID: C_2538750_10) genotypes were determined using DNA isolated from the blood samples with a salting out method ([@B74]). Genotyping was performed using the primers and probes from the TaqMan^®^ Drug Metabolism Genotyping Assays (Applied Biosystems, Foster City, CA, United States) on ABI Prism 7300 Real time PCR System apparatus (Applied Biosystems, Foster City, CA, United States), according to the procedures described by Applied Biosystems. The 10 μL reaction volume contained 30--100 ng of DNA. Around 10% of randomly selected samples were genotyped again as a quality control for genotyping assays.

Statistical Analyses
--------------------

Data were analyzed using Graph Prism version 7.00 (GraphPad Software, Inc.). Data distribution normality was determined with the Kolmogorov--Smirnov normality test. Due to the lack of a normal distribution, Kruskal--Wallis analysis of variance (ANOVA) and Dunn *post hoc* were used to assess differences in age, chlorpromazine equivalent doses, PANSS total, positive, negative, and general psychopathology scores between different groups of patients. The Hardy--Weinberg equilibrium (HWE) was determined using χ^2^-test ([@B92]). Smoking status, as well as genotype and haplotype distributions, between male and female patients with TRS and non-TRS, were also compared using χ^2^-test ([@B92]). To assess which category was a major contributor to rejecting the null hypothesis, standardized residuals (*R*; [@B36]) were calculated. Haploview software v. 4.2 ([@B5]) was used to determine LD pairwise values for *COMT* rs4818 and rs4680. Loci are considered to be in linkage disequilibrium if *D*′ coefficient is \>0.80. Best-estimate haplotype pair for every patient was assigned by PLINK v. 1.07 software using the expectation--maximization algorithm ([@B88]). Besides genotypic and haplotypic analyses, additional genetic models ([@B42]) were evaluated: dominant model (G carriers, i.e., GG + GA vs. AA) and recessive model (A carriers, i.e., GA + AA vs. GG) for the *COMT* rs4680, as well as dominant model (C carriers, i.e., CC + CG vs. GG) and recessive model (G carriers, i.e., GG + GC vs. CC) for the *COMT* rs4818. For individual SNP analysis the *p*-value (0.05/2 = 0.025) was corrected because two SNPs were compared and the results were considered significant if *p* \< 0.025. G^∗^Power 3 Software ([@B35]) was used to determine a priori sample size. For a χ^2^-test \[with α = 0.025; with expected small effect size = 0.2; power (1 - β) = 0.800\], the required sample size was *N* = 288 with *df* = 2; or *N* = 238 for *df* = 1. For Kruskal--Wallis ANOVA, the *p*-value (0.05/4 = 0.0375) was corrected because of four groups into α = 0.0375; with expected small effect size = 0.15; and power (1 - β) = 0.800\]; the required sample size was 528. As the study included 931 participants, it had adequate sample size and statistical power to detect significant differences among the groups.

Results
=======

Clinical and Demographic Data
-----------------------------

Treatment-resistance (TRS) differed significantly (χ^2^ = 69.694; *df* = 1; *p* \< 0.001) between male and female patients, since males were more frequently treatment resistant (79.6%) than females (20.4%), and the lowest number of female TRS patients (*R* = 5.4) significantly contributed to this significance. Therefore, in further analyses all TRS and non-TRS patients were subdivided according to gender (**Table [1](#T1){ref-type="table"}**).

###### 

The demographic and clinical data of male and female patients with schizophrenia subdivided in TRS and non-TRS groups.

                                                                               TRS (*N* = 270)   Non-TRS (*N* = 661)                                   
  ---------------------------------------------------------------------------- ----------------- --------------------- --------------- --------------- -----------------------------------------------------------------
  Age (years) (median, 25 and 75 percentile)                                   39 (30,45)        48 (38,58)            40 (31,49)      50 (39,57)      *H* = 106.086; *df* = 3; *p* \< 0.001^∗^; Kruskal--Wallis ANOVA
  Smokers, *N* (%)                                                             155 (72.09%)      27 (49.09%)           220 (66.67%)    172 (51.96%)    χ^2^ = 198.8; *df* = 3; *p* \< 0.0001^∗^; χ^2^-test
  PANSS total scores (median, 25 and 75 percentile)                            130 (115,143)     106 (98,124)          105 (92,123)    90 (75,102)     *H* = 324.222; *df* = 3; *p* \< 0.001^∗^; Kruskal--Wallis ANOVA
  PANSS positive scores (median, 25 and 75 percentile)                         34 (30,39)        28 (26,32)            26 (22,33)      22 (17,26)      *H* = 300.511; *df* = 3; *p* \< 0.001^∗^; Kruskal--Wallis ANOVA
  PANSS negative scores (median, 25 and 75 percentile)                         34 (28,37)        27 (23,30)            26 (23,31)      23 (19,26)      *H* = 248.191; *df* = 3; *p* \< 0.001^∗^; Kruskal--Wallis ANOVA
  PANSS general psychopathology scores (median, 25 and 75 percentile)          62 (56,69)        54 (48,63)            52 (45,59)      45 (38,51)      *H* = 279.877; *df* = 3; *p* \< 0.001^∗^; Kruskal--Wallis ANOVA
  Chlorpromazine equivalent doses, mg/per day (median, 25 and 75 percentile)   700 (500,1000)    500 (400,750)         500 (300,750)   400 (200,500)   *H* = 136.508; *df* = 3; *p* \< 0.001^∗^; Kruskal--Wallis ANOVA

Results are presented as medians with 25 and 75 percentile.

N

is the number of patients.

∗

Significant differences between male and female TRS and non-TRS patients. Non-TRS, non-treatment-resistant schizophrenia; PANSS, Positive and Negative Syndrome Scale; TRS, treatment-resistant schizophrenia.

Dunn *post hoc* analysis performed following Kruskal--Wallis ANOVA confirmed significant difference (*p* \< 0.001) in age, chlorpromazine equivalent doses, PANSS total, positive, negative, and general psychopathology scores between male and female patients in TRS, as well as in non-TRS group. Moreover, there were also significant differences (*p* \< 0.001) between male patients with TRS and non-TRS, as well as between female patients with TRS and non-TRS, in chlorpromazine equivalent doses, PANSS total, positive, negative, and general psychopathology scores, but not in the age.

As shown in **Table [1](#T1){ref-type="table"}**, the distribution of smokers and non-smokers was also significantly different (*p* \< 0.0001) between male and female patients with TRS and non-TRS. Significantly (*R* = 2.86) lower frequency of female non-smokers in non-TRS group contributed to this difference. Males smoked more often than females in both TRS (χ^2^ = 10.55; *df* = 1; *p* = 0.0012) and no-TRS group (χ^2^ = 15.27; *df* = 1; *p* \< 0.0001); however, there were no significant differences between male patients with TRS and non-TRS, as well as between female patients with TRS and non-TRS.

Genotype Analysis
-----------------

In male patients with schizophrenia, in the TRS group, *COMT* rs4818 (χ^2^ = 1.333; *df* = 1; *p* = 0.248) and *COMT* rs4680 (χ^2^ = 0.929; *df* = 1; *p* = 0.335) genotypes distributions did not deviate from HWE. In male patients who were not treatment resistant (i.e., in non-TRS group), no departure from HWE was found for *COMT* rs4818 (χ^2^ = 0.447; *df* = 1; *p* = 0.503) and *COMT* rs4680 (χ^2^ = 1.492; *df* = 1; *p* = 0.222) genotypes. In female TRS patients, no significant deviation from HWE in *COMT* rs4818 (χ^2^ = 1.603; *df* = 1; *p* = 0.206) and *COMT* rs4680 (χ^2^ = 0.197; *df* = 1; *p* = 0.657) genotypes distributions was detected. Among female patients in non-TRS group, frequencies of *COMT* rs4818 (χ^2^ = 0.981; *df* = 1; *p* = 0.322) and *COMT* rs4680 (χ^2^ = 0.114; *df* = 1; *p* = 0.736) genotypes did not deviate from HWE.

There were no significant differences in the frequency of the genotypes or in the dominant or recessive model for the *COMT* rs4818 and COMT rs4680 between male patients with or without TRS (**Table [2](#T2){ref-type="table"}**).

###### 

The distribution of the *COMT* rs4818 and rs4680 genotypes in male patients with schizophrenia subdivided into TRS and non-TRS groups.

  Male patients (*N* = 545)                TRS (*N* = 215)   Non-TRS (*N* = 330)                
  --------------------------- ------------ ----------------- --------------------- ----- ------ -------------------------
  COMT rs4818 genotypes       CC           60                27.9                  83    25.2   χ^2^ = 2.315; *df* = 2;
                              CG           99                46.0                  171   51.8   *p* = 0.314; χ^2^-test
                              GG           56                26.0                  76    23.0   
  C carriers                  C carriers   159               74.0                  254   77.0   χ^2^ = 0.911; *df* = 1;
                              GG           56                26.0                  76    23.0   *p* = 0.340; χ^2^-test
  G carriers                  G carriers   155               72.1                  247   74.8   χ^2^ = 0.671; *df* = 1;
                              CC           60                27.9                  83    25.2   *p* = 0.413; χ^2^-test
  COMT rs4680 genotypes       AA           85                39.5                  119   36.1   χ^2^ = 1.741; *df* = 2;
                              AG           95                44.2                  167   50.6   *p* = 0.419; χ^2^-test
                              GG           35                16.3                  44    13.3   
  A carriers                  A carriers   180               83.7                  286   86.7   χ^2^ = 0.645; *df* = 1;
                              GG           35                16.3                  44    13.3   *p* = 0.422; χ^2^-test
  G carriers                  G carriers   130               60.5                  211   63.9   χ^2^ = 0.511; *df* = 1;
                              AA           85                39.5                  119   36.1   *p* = 0.475; χ^2^-test

Results are presented as numbers and %.

N

is the number of patients. COMT, catechol-

O

-methyl-transferase; C carriers of the COMT rs4818, the combined CC and CG genotype; G carriers of the COMT rs4818, the combined GG and GC genotype; G carriers of the COMT rs4680, the combined GG and AG genotype; A carriers of the COMT rs4680, the combined AA and AG genotype; non-TRS, non-treatment-resistant schizophrenia; TRS, treatment-resistant schizophrenia.

In female patients (**Table [3](#T3){ref-type="table"}**) subdivided into TRS and non-TRS groups, significant differences were found in the frequency of the *COMT* rs4818 genotypes (CC, CG, and GG; *p* = 0.014) and in the dominant model (C carriers, i.e., CC + CG vs. GG; *p* = 0.008). The distribution of the genotypes in the recessive model (G carriers, i.e., GG + GC vs. CC; *p* = 0.043) for the *COMT* rs4818 did not differ significantly between female TRS and non-TRS groups (**Table [3](#T3){ref-type="table"}**). Further analysis revealed that the C carriers were five times more likely to be in the TRS group than GG homozygotes \[odds ratio (OR) (C carriers/GG) = 5.748; 95% confidence interval (CI) (1.362--24.251), *z* = 2.381; *p* = 0.017\] in female patients with schizophrenia. Similar frequency of the *COMT* rs4680 genotypes (GG, GA and AA), and the genotypes in the recessive (A carriers, i.e., GA + AA vs. GG) or dominant (G carriers, i.e., GG + GA vs. AA) model was found in female TRS and non-TRS patients (**Table [3](#T3){ref-type="table"}**). Although a difference in the distribution of the G carriers vs. AA homozygotes was not significant (*p* = 0.033) due to correction (*p* = 0.025), female carriers of AA genotype of the *COMT* rs4680 were slightly more frequent in TRS group than G carriers (*R* = 1.7; OR (AA homozygotes/ G carriers) = 1.917, 95% CI (1.046--3.515); *z* = 2.105; *p* = 0.035). These results showed that female AA homozygotes had almost double chance to develop TRS when compared to G carriers in female patients with schizophrenia (**Table [3](#T3){ref-type="table"}**).

###### 

The distribution of the *COMT* rs4818 and rs4680 genotypes in female patients with schizophrenia subdivided into TRS and non-TRS group.

  Female patients (*N* = 386)                TRS (*N* = 55)   Non-TRS (*N* = 331)                
  ----------------------------- ------------ ---------------- --------------------- ----- ------ ----------------------------
  COMT rs4818 genotypes         CC           28               50.9                  121   36.6   χ^2^ = 8.525; *df* = 2;
                                CG           25               45.5                  151   45.6   *p* = 0.014^∗^; χ^2^- test
                                GG           2                3.6                   59    17.8   
  C carriers                    C carriers   53               96.4                  272   82.2   χ^2^ = 7.136; *df* = 1;
                                GG           2                3.6                   59    17.8   *p* = 0.008^∗^; χ^2^-test
  G carriers                    G carriers   27               49.1                  210   63.4   χ^2^ = 4.100; *df* = 1;
                                CC           28               50.9                  121   36.6   *p* = 0.043; χ^2^-test
  COMT rs4680 genotypes         AA           20               36.4                  76    23.0   χ^2^ = 5.263; *df* = 2;
                                AG           25               45.5                  162   48.9   *p* = 0.072; χ^2^-test
                                GG           10               18.2                  93    28.1   
  A carriers                    A carriers   45               81.8                  238   71.9   χ^2^ = 2.370; *df* = 1;
                                GG           10               18.2                  93    28.1   *p* = 0.124; χ^2^-test
  G carriers                    G carriers   35               63.6                  255   77.0   χ^2^ = 4.534; *df* = 1;
                                AA           20               36.4                  76    23.0   *p* = 0.033; χ^2^-test

Results are presented as numbers and %.

N

is the number of patients.

∗

Significant difference in the distribution of the CC, CG, and GG genotypes; or of the C carriers and GG homozygotes, between TRS and non-TRS patients. COMT, catechol-

O

-methyl-transferase; C carriers of the COMT rs4818, the combined CC and CG genotype; G carriers of the COMT rs4818, the combined GG and GC genotype; G carriers of the COMT rs4680, the combined GG and AG genotype; A carriers of the COMT rs4680, the combined AA and AG genotype; non-TRS, non-treatment-resistant schizophrenia; TRS, treatment-resistant schizophrenia.

Haplotype Analysis
------------------

To further examine the association of *COMT* rs4818 and rs4680 polymorphisms with TRS in male and female patients, a haplotype analysis was performed. As shown in **Figure [1](#F1){ref-type="fig"}**, a high degree of linkage disequilibrium (*D*′ = 0.88) was revealed for *COMT* rs4818 and rs4680 polymorphisms.

![Linkage disequilibrium (LD) plot with D' values characterizing haplotype blocks in COMT gene. The plot was generated by Haploview 4.2 software. Block definition followed the rules of solid spine of LD. D' values multiplied by 100 are shown as a number in the diamonds.](fphar-09-00705-g001){#F1}

**Table [4](#T4){ref-type="table"}** shows the frequencies of the *COMT* (rs4818-rs4680) haplotypes in all patients subdivided in TRS and non-TRS group. The most common haplotype was C-A, followed by G-G haplotype. There was a significant difference (*p* = 0.037) in the distribution of G-G haplotype among TRS and non-TRS patients, demonstrating that G-G haplotype was less frequently represented in TRS than in non-TRS group (**Table [4](#T4){ref-type="table"}**).

###### 

The distribution of *COMT* rs4680-rs4818 haplotypes in all patients with schizophrenia subdivided into TRS and non-TRS group.

  Haplotype   All patients   TRS, Non-TRS   
  ----------- -------------- -------------- -----------------------------------------
  C-A         48.0           49.4, 47.4     χ^2^ = 0.585; *p* = 0.444; χ^2^-test
  G-G         36.3           32.7, 37.8     χ^2^ = 4.436; *p* = 0.037^∗^; χ^2^-test
  C-G         13.5           14.7, 13.0     χ^2^ = 1.019: *p* = 0.313; χ^2^-test
  G-A         2.2            3.2, 1.8       χ^2^ = 3.422; *p* = 0.064; χ^2^-test

Results are presented as %. COMT, catechol-

O

-methyl-transferase; non-TRS, non-treatment-resistant schizophrenia; TRS, treatment-resistant schizophrenia.

∗

Significant differences in the frequency of G-G haplotype between TRS and non-TRS patients.

In the analysis of the *COMT* rs4818-rs4680 haplotypes, all patients were subdivided into carriers and non-carriers of the particular haplotype. For two of the most common haplotype (C-A and G-G) groups, subjects were additionally subdivided into "homozygotes" for the particular haplotype (carriers of the two same haplotype groups), individuals that carry only one of the examined haplotype, and non-carriers of the tested haplotype. Because of the low frequency of the "homozygotes", for another two haplotype groups (C-G and G-A), patients were divided only into carriers and non-carriers.

Haplotype analysis showed a lack of significant difference in the frequency of the particular haplotypes between male TRS and non-TRS patients (**Table [5](#T5){ref-type="table"}**).

###### 

Haplotype frequencies of *COMT* rs4680 and rs4818 polymorphisms in male patients with schizophrenia subdivided according to the TRS.

  Male patients (*N* = 565)                  TRS (*N* = 215)   Non-TRS (*N* = 330)                
  --------------------------- -------------- ----------------- --------------------- ----- ------ -------------------------
  Haplotype C- A              C-A/C-A        52                24.2                  75    22.7   χ^2^ = 2.494; *df* = 2;
                              C-A/^∗^        102               47.4                  178   53.9   *p* = 0.287; χ^2^-test
                              ^∗^/^∗^        61                28.40                 77    23.3   
  C-A carriers                C-A carriers   154               71.6                  253   76.7   χ^2^ = 1.748; *df* = 1;
                              Non-carriers   61                28.4                  77    23.3   *p* = 0.186; χ^2^-test
  Haplotype G-G               G-G/ G-G       30                14.0                  43    13.0   χ^2^ = 1.730; *df* = 2;
                              G-G/^∗^        92                42.8                  160   48.5   *p* = 0.421; χ^2^-test
                              ^∗^/^∗^        93                43.3                  127   38.5   
  G-G carriers                G-G carriers   122               56.7                  203   61.5   χ^2^ = 1.231; *df* = 1;
                              Non-carriers   93                43.3                  127   38.5   *p* = 0.267; χ^2^-test
  C-G carriers                C-G carriers   49                22.8                  77    23.3   χ^2^ = 0.022; *df* = 1;
                              Non-carriers   166               77.2                  253   76.7   *p* = 0.883; χ^2^-test
  G-A carriers                G-A carriers   12                5.6                   9     2.7    χ^2^ = 2.862; *df* = 1;
                              Non-carriers   203               94.4                  321   97.3   *p* = 0.091; χ^2^-test

∗

Other haplotypes. Results are presented as numbers and %.

N

is the number of patients. COMT, catechol-

O

-methyl-transferase; non-TRS, non-treatment-resistant schizophrenia; TRS, treatment-resistant schizophrenia.

In female (**Table [6](#T6){ref-type="table"}**) patients with schizophrenia, haplotype distribution differed significantly between TRS and non-TRS patients. Among female schizophrenia patients, haplotype G-G was detected less frequently in TRS group (*R* = 1.5; *p* = 0.011) compared to non-TRS group. Detailed analysis showed that female non-carriers of the haplotype G-G were 2 times more likely to be treatment resistant than female carriers of the haplotype G-G (OR (non-carriers/GG carriers) = 2.1015; 95% CI (1.179--3.743); *z* = 2.522; *p* = 0.012). Haplotype analysis confirmed genotyping results since haplotype frequency of G-G/G-G, G-G/^∗^ and ^∗^/^∗^ haplotypes between female TRS and non-TRS patients differed significantly (*p* = 0.009). Namely, presence of the G allele was "protective" against TRS. The high activity G-G/G-G haplotype was the rarest haplotype (3.6%) in female patients with TRS, followed by G-G/^∗∗^ haplotype, while carriers of any other haplotype than G-G were overrepresented (56.4%) in female patients with TRS in comparison to non-TRS female patients (**Table [6](#T6){ref-type="table"}**).

###### 

Haplotype frequencies of *COMT* rs4680 and rs4818 polymorphisms in female patients with schizophrenia subdivided according to the TRS.

  Female patients (*N* = 386)                  TRS (*N* = 55)   Non-TRS (*N* = 331)                
  ----------------------------- -------------- ---------------- --------------------- ----- ------ --------------------------
  Haplotype C-A                 C-A/C-A        17               30.9                  71    21.5   χ^2^ = 4.198; *df* = 2;
                                C-A/^∗^        28               50.9                  161   48.6   *p* = 0.123; χ^2^-test
                                ^∗^/^∗^        10               18.2                  99    29.9   
  C-A carriers                  C-A carriers   45               81.8                  232   70.1   χ^2^ = 3.201; *df* = 1;
                                Non-carriers   10               18.2                  99    29.9   *p* = 0.074; χ^2^-test
  Haplotype G-G                 G-G/G-G        2                3.6                   53    16.0   χ^2^ = 9.318; *df* = 2;
                                G-G/^∗^        22               40.0                  152   45.9   *p* = 0.009\#; χ^2^-test
                                ^∗^/^∗^        31               56.4                  126   38.1   
  G-G carriers                  G-G carriers   24               43.6                  205   61.9   χ^2^ = 6.544; *df* = 1;
                                Non-carriers   31               56.4                  126   38.1   *p* = 0.011\#; χ^2^-test
  C-G carriers                  C-G carriers   15               27.3                  81    24.5   χ^2^ = 0.198; *df* = 1;
                                Non-carriers   40               72.7                  250   75.5   *p* = 0.656; χ^2^-test
  G-A carriers                  G-A carriers   3                5.5                   8     2.4    χ^2^ = 1.572; *df* = 1;
                                Non-carriers   52               94.5                  323   97.6   *p* = 0.210; χ^2^-test

∗

Other haplotypes. Results are presented as numbers and %.

N

is the number of patients. COMT, catechol-

O

-methyl-transferase; non-TRS, non-treatment-resistant schizophrenia; TRS, treatment-resistant schizophrenia. \#Significant differences in the frequency of G-G/G-G, G-G/

∗

and

∗

/

∗

haplotypes between TRS and non-TRS patients.

Discussion
==========

Clinical Differences Between Patients With TRS and Non-TRS
----------------------------------------------------------

Our findings of four times higher prevalence of TRS in male compared to female patients are in contrast to results from Danish patients ([@B119]) who had higher rates of TRS in female patients. However, this study used different methodology, such as the determination of TRS by a treatment-based proxy ([@B119]). In our study, both male and female patients with TRS had significantly higher PANSS total, positive, negative, and general psychopathology scores, as well as higher chlorpromazine equivalent doses in comparison to male and female patients in non-TRS group. This is in agreement with previous studies reporting that patients with TRS had more severe symptomatology as measured by PANSS ([@B75]) and received higher total antipsychotic dose presented as chlorpromazine equivalents, compared to patients with non-TRS ([@B50]; [@B19]; [@B75]). In the present study, the concentration of antipsychotics in plasma was not measured. While about one-third of patients with TRS had sub-therapeutic or non-detectable antipsychotic plasma levels ([@B72]), non-adherence, or only partial adherence in some of our patients with TRS cannot be ruled out. However, unlike the latter article which excluded patients on long-acting antipsychotics ([@B72]), in the present study about a quarter of patients received different depot antipsychotics (data not shown), which provided continuous drug delivery. Furthermore, while the majority of patients with TRS were hospitalized at the time of the assessment, antipsychotic intake was monitored by hospital stuff. Given the pronounced difference (an average of 100--200 mg/per day) in chlorpromazine equivalents between individuals with and without TRS, some of those patients might developed the antipsychotic-induced dopamine suprasensitivity psychosis (DSST). Although the presence of neurological disorders was exclusion criteria, rating scales for the assessment of movement disorders were not performed. Therefore, while subjects with pronounced extrapyramidal symptoms or tardive dyskinesia were not included, subtle movement disorders, indicative of DSST ([@B16]), might have gone undetected in some individuals. In the present study, the prevalence of smoking was higher in males than females, in both patients with TRS and non-TRS. This is in line with our previous data showing higher prevalence of smoking in male (64%) than in female (46%) patients with schizophrenia ([@B80]), and agrees with the data from general population, given that the men had higher smoking prevalence than woman in European countries, including Croatia ([@B39]). Men with schizophrenia also had higher rates of nicotine dependence and different smoking habits compared to healthy men ([@B80]; [@B98]). However, the rate of smoking in our study was similar in patients with TRS and non-TRS, which is consistent with the finding from the smaller sample of 21 patients with TRS and 20 patients with non-TRS ([@B76]). Although patients with schizophrenia have the highest known rates of smoking ([@B21]), confirmed by the 62.8% of smokers found in schizophrenia patients in our previous study ([@B79]), our results suggest that treatment-resistance does not further increase this rate. However, smoking might be related to more severe clinical presentation in patients with TRS, since smokers with TRS had higher PANSS total scores and negative subscale scores, and performed significantly worse on the problem solving cognitive task, compared to TRS patients who did not smoke ([@B53]). The relationship between schizophrenia and smoking is complex ([@B97]) given that smoking status was also related to lower total PANSS scores and the PANSS general psychopathology scores in patients with schizophrenia ([@B79]). Smoking might contribute to treatment resistance by decreasing serum levels of clozapine and olanzapine, but the dose increase might overcome those effects ([@B114]).

Gender-Related Differences in the COMT rs4680 and rs4818 Genotypic and Haplotypic Association With Treatment Resistance
-----------------------------------------------------------------------------------------------------------------------

Our results confirmed gender-related differences in the genotypic and haplotypic association of the *COMT* rs4680 and rs4818 and treatment resistance in patients with schizophrenia. Namely, our study revealed that: (1) in male patients with schizophrenia, there were no significant haplotypic and genotypic associations between *COMT* rs4680 and rs4818 and treatment-resistance; (2) in female patients with TRS, AA genotype carriers of the *COMT* rs4680 were nominally more frequently present compared to G carriers, whereas CC carriers of the *COMT* rs4818 were significantly more frequent than G carriers; (3) in female patients with TRS, the high activity G-G/G-G *COMT* haplotype was rare, followed by G-G/^∗∗^ haplotype, while carriers of any other than G-G haplotype were overrepresented, in comparison to female patients with non-TRS. To the best of our knowledge, this is the first report to document that the presence of high-activity (G variants) of the *COMT* rs4680 and rs4818, and *COMT* G-G/G-G haplotype, appears to be associated with lower risk of TRS in female patients with schizophrenia, while no such associations were observed in men. These findings suggest the significant, but gender-specific associations of *COMT* variants with the development of treatment-resistance in schizophrenia.

Gender-Related Association Between the COMT rs4680 Genotype and Treatment Resistance
------------------------------------------------------------------------------------

Gender differences were previously noticed in COMT activity ([@B14]) as well as in distribution of the *COMT* rs4680 genotypes in healthy individuals ([@B44]; [@B31]) and patients with schizophrenia ([@B8]). There is also evidence of distinct, sex-dependent brain changes related to *COMT* rs4680 polymorphism ([@B8]; [@B31]). Female patients with schizophrenia, carriers of the *COMT* rs4680 AA genotype, had smaller volumes of caudate, putamen, and pallidum, while male patients, homozygous for the Met allele showed higher or similar subcortical volumes compared to other groups ([@B8]). In healthy volunteers, male GG homozygotes had higher white matter integrity compared to A carriers, whereas no differences were observed in females ([@B31]). In healthy women, carriers of the *COMT* rs4680 AA genotype had reduced and GG genotype carriers had superior cognitive flexibility, whereas in men no association with cognition was found ([@B44]). Those studies suggested that AA homozygosity, specifically in women, might be adversely associated with cognitive functioning ([@B44]) and subcortical brain volumes ([@B8]), which could be also related to the association of *COMT* rs4680 polymorphism with treatment-resistance observed only in female patients with schizophrenia in the present study. On the other hand, some studies have not observed associations of *COMT* rs4680 polymorphism with age or gender ([@B117]; [@B17]; [@B4]).

Four studies have addressed the association between *COMT* rs4680 and TRS so far. Two of them have included only patients with TRS ([@B10]; [@B90]) whereas two other trials included patients with both TRS and non-TRS ([@B55]; [@B113]). The discrepancies across the studies might arise from sex-differences, ethnic differences, diversities in the populations studied, limited power and small sample sizes, as well as different methodology such as the various definitions of treatment-resistance and measurements of psychopathology. In contrast to our results, TRS patients, carriers of the AA or GA genotypes of the *COMT* rs4680, but who were also carriers of one or two DRD4 120-bp alleles (120/240 and 120/120), experienced better response to clozapine than TRS patients, carriers of the GG genotype ([@B90]). This study included 93 TRS patients of South Indian ethnicity, but did not divide patients according to gender. Corresponding to our results in male patients with schizophrenia, *COMT* rs4680 genotypes were not associated with better response to clozapine in TRS ([@B90]). Since in our study the presence of the A allele was associated with TRS in female but not in male patients, either different number of patients, the fact that we did not evaluate gene-gene interaction with the DRD4 120-bp alleles, or ethnic differences ([@B90]), might explain these different results. In line with the results from the study evaluating 107 treatment-resistant Italian patients ([@B10]), carriers of the *COMT* rs4680 GG genotype have shown better response to clozapine (in reducing negative symptoms), compared to patients with the GA and AA genotypes ([@B10]). In our study, this slight association was observed only in female but not in male patients. Since the cited study ([@B10]) did not evaluate gender specific association with TRS, and included much smaller sample, we might speculate that this non-significant association (due to correction) of the AA genotype with TRS might be presumably related to female gender. Our results on the link between the AA genotype and TRS in female patients with schizophrenia also agree with the data from the 100 Japanese patients with schizophrenia ([@B55]). In this study, patients with TRS had marginally higher frequency of the A variant of *COMT* rs4680 polymorphism, and the odds ratio for the AA genotype in TRS was 4.392 ([@B55]). Patients with the *COMT* rs4680 AA genotype also received higher chlorpromazine equivalent doses compared to carriers of the GA and GG genotypes ([@B55]). Although the sample size was small (only eight patients had *COMT* rs4680 AA genotype), and patients were not evaluated according to gender ([@B55]), these results are in line with our female data. In agreement with our data in males, but in contrast to data obtained in female patients with or without TRS, no difference in the *COMT* rs4680 genotype frequency was detected in 138 patients: 44 treatment-resistant and 94 treatment-responsive patients from Slovenia, who were not divided by gender ([@B113]).

### Gender-Related Association Between the COMT rs4818 Genotype and Treatment Resistance

While *COMT* rs4680 is among the most frequently investigated polymorphisms in treatment response to psychotropic drugs, only a few studies investigated *COMT* rs4818 polymorphism and the response to antipsychotics ([@B43]; [@B120]; [@B103]). In our study the presence of the CC genotype of the *COMT* rs4818 in female, but not in male group of patients with TRS, was found significantly more frequently than the presence of the GC and GG genotypes. In line with our findings, in the large Shanghai cohort of 995 Chinese patients with schizophrenia, C carriers of the *COMT* rs4818 had more frequently poor response to quetiapine ([@B120]). The association between *COMT* rs4818 and treatment response to risperidone was also reported in 288 Shanghai patients with schizophrenia ([@B103]), but opposed to our and their previous ([@B120]) results, the G/C allele frequency was similar between good and poor responders ([@B103]).

Gender-Related Association Between the COMT rs4680 and rs4818 Haplotype and TRS
-------------------------------------------------------------------------------

The findings of the present study that carriers of the high activity G-G/G-G haplotype were more frequently observed in non-TRS female group, whereas female carriers of any other haplotype than G-G were overrepresented in the group of patients with TRS, suggest that presence of the G allele might be associated with decreased risk of TRS. This association was also confirmed in Shanghai cohort ([@B120]). In contrast to our data, among 117 patients with schizophrenia of the southern Indian origin, the *COMT* haplotype C-A (rs4818-r4680) was observed more often in responders to risperidone, compared to non-responders ([@B43]). However, these data were not analyzed by gender, and the treatment-response was defined only by the clinical global impression scale ([@B43]).

Our results showed that presence of the high activity (i.e., G variants) of the *COMT* was associated with lower risk of TRS in female patients. Likewise, negative symptoms of schizophrenia were less severe in female patients carrying the high activity *COMT* variants (rs740603 (G)-rs4818 (G) haplotype), but this effect was not observed in male patients with schizophrenia ([@B71]). If this finding will be confirmed in larger studies and meta-analyses, women with schizophrenia who are carriers of the *COMT* rs4680 and rs4818 low-activity haplotypes, might require different treatment approach, such as early clozapine initiation ([@B107]), clozapine augmentation with different antiepileptic drugs ([@B121]), or electroconvulsive therapy (ECT) ([@B116]).

The Association Between the High-Activity COMT Haplotype and Treatment Response in Female Patients With Schizophrenia: Possible Explanations
--------------------------------------------------------------------------------------------------------------------------------------------

COMT activity plays a key role in the regulation of dopamine activity in PFC, while its role in the regulation of striatal dopamine turnover is less important due to higher abundance of dopamine transporter in this region ([@B7]). In line with this hypothesis, in healthy subjects, *COMT* rs4680 GG carriers had lower dopamine tone in cortical and limbic regions, compared to carriers of the GA or AA genotypes, while no changes of dopamine tone were detected in the striatal regions ([@B108]). However, striatal dopamine turnover seems to be altered in patients with TRS ([@B61]). While patients with schizophrenia generally exhibited elevated striatal dopamine synthesis capacity compared to healthy controls ([@B38]), individuals suffering from TRS had lower capacity of dopamine synthesis in striatum ([@B61]). This finding was observed in TRS patients treated with clozapine ([@B61]) and in patients treated with other antipsychotics ([@B23]), in comparison to patients who responded to antipsychotic treatment. Although COMT has a minor role in metabolizing striatal dopamine, modifications of COMT activity may affect dopamine signaling also in the striatum, as shown by the data from animal models ([@B105]; [@B111]), and from some ([@B9]) but not all ([@B108]) human reports. Considering that compensatory mechanisms might influence dopamine function in striatum ([@B105]), the relationship between prefrontal dopamine availability, modulated by *COMT* rs4680, and striatal dopamine tone ([@B7]; [@B12]) was proposed. In post-mortem brain samples of individuals without psychiatric disorders, carriers of the *COMT* rs4680 GG genotype had greater expression of tyrosine hydroxylase mRNA in mesencephalic dopamine neurons than GA genotype carriers, particularly in neuronal populations that project to the striatum, suggesting higher dopamine synthesis in striatal regions of GG homozygotes ([@B1]).

Although these studies did not account the possible gender differences ([@B1]; [@B108]), we might speculate that females with AA genotype of the *COMT* rs4680 might have had higher prefrontal and compensatory lower striatal dopamine levels, which were reported in patients with TRS ([@B61]). The dopamine synthesis capacity in striatum was proposed as a biomarker for TRS ([@B61]). In the presence of higher dopamine stimulation from PFC, such as in the *COMT* rs4680 AA homozygous subjects, dopamine release might decrease in striatum in an attempt to protect the brain from excessive dopaminergic stimulation, and this mechanism might be related to treatment-resistance. According to our findings, this hypothesis might be only relevant for female patients with schizophrenia. Given the COMT-inhibiting properties of estradiol ([@B73]), decreased COMT activity in women ([@B14]), and large sex-differences in dopaminergic cortical pathways in preclinical model ([@B65]), it could be hypothesized that women have higher PFC dopamine levels than men, carrying the same *COMT* genotype. Such greater dopaminergic stimulation in females could lead to a gender-specific hyperdopaminergic overdrive in PFC, and consequently to decreased dopamine levels in striatum, which might eventually predispose women to TRS. This proposal fits the presumption that some patients do not respond to treatment because they do not exhibit elevated dopamine input in striatum ([@B23]; [@B61]), while increased dopamine stimulation in striatum is the target for antipsychotic drugs ([@B38]). However, the current study did not measure dopamine levels.

The evidence of sexual dimorphism of *COMT* gene is still inconclusive, but continues to accumulate ([@B46]). The findings regarding sex-dependent associations of COMT with various clinical and biological features have been reported in diverse populations ([@B95]; [@B69]; [@B13]; [@B56]; [@B63]; [@B64]), as well as in preclinical trials ([@B41]; [@B66]; [@B99]). In general, sexually dimorphic effects of *COMT* gene variations are complex, and range from robust to subtle, depending on the parameters, which were measured.

Great amount of the data demonstrating gender differences in association of *COMT* gene with various personality traits, phenotypes, cognitive domains and behaviors, came from studies that enrolled healthy individuals ([@B30]; [@B34]; [@B82]; [@B109]; [@B62]; [@B6]; [@B69]; [@B20]; [@B18]). However, sexual dimorphism of *COMT* gene has been also reported in various neuropsychiatric disorders such as anxiety disorders, depression, attention deficit hyperactivity disorder, and obsessive-compulsive disorder ([@B57], [@B58]; [@B28], [@B27]; [@B86]; [@B25]; [@B93]; [@B85]; [@B11]; [@B2]). In addition, our results are in line with other studies demonstrating sex-specific associations of *COMT* variants in patients with schizophrenia ([@B104]; [@B24]; [@B95]; [@B70]). All these data suggest that *COMT* gene variations might contribute to the sex differences in brain function and structure ([@B26]; [@B118]; [@B99], [@B100]; [@B32]), and consequently result in sexual dimorphism in the predisposition to various neuropsychiatric disorders. Sex-specific effects of COMT gene are usually attributed to transcriptional regulation by estrogens, and it has been suggested that reciprocal and partly genotype-influenced interactions between COMT and estrogens may be relevant to sexual dimorphism ([@B46]). Although the biological reason why COMT association is sex-specific is still not clear, it has been hypothesized that COMT genotype may modulate the role of estrogens in brain function and dysfunction ([@B102]), while estrogens affect COMT activity and its pathophysiological consequences by influencing the COMT gene expression ([@B46]). However, additional mechanisms are also possible. Nevertheless, it is known from various studies that sex differences in the genetic architecture of many human traits and psychiatric disorders are common. Namely, in addition to COMT, sexually dimorphic genetic associations with psychiatric phenotypes have been reported also for other autosomal genes such as HTR2A ([@B33]), MTHFR ([@B101]; [@B60]), and AC7 ([@B47]). Therefore, our findings reporting sex-specific associations of COMT variants with the development of treatment-resistance in schizophrenia also contribute to the knowledge in this field.

Limitations of the Study
------------------------

Limitation of the study is the fact that treatment-resistance in schizophrenia patients was determined retrospectively. Another limitation of this investigation is the lower number of female then male patients, which resulted in a limited representation of some of the genotypes after the gender-stratified analysis was conducted. Therefore, the obtained results require replication in a larger sample.

Conclusion
==========

Our findings reveal complex and gender-dependent genotypic and haplotypic associations between *COMT* rs4680 and rs4818 and TRS. In males with schizophrenia, treatment-resistance was not associated with the *COMT* rs4818 and rs4680 genotypes or haplotypes. In contrast, as far as we are aware, this is the first study to show that in female patients with schizophrenia, the presence of high-activity (G variants) of the *COMT* rs4680 and rs4818 polymorphisms, and the presence of the G-G/G-G haplotype, is associated with the lower risk of TRS. These findings extend previously reported gender-related association of *COMT* rs4680 variants and TRS, and for the first time detect gender-dependent association of *COMT* rs4818 polymorphism with treatment-resistance in patients with schizophrenia. Accordingly, we might speculate that determination of the *COMT* rs4680 and rs4818 genotypes and haplotypes early in the course of treatment might help in the prediction of the treatment-resistance in female patients with schizophrenia. However, those findings must be interpreted with caution, given that the number of included females was substantially lower than the number of males. Therefore, investigation of the genotypic and haplotypic association between *COMT* SNPs rs4680 and rs4818 and TRS in the larger sample of females with schizophrenia is warranted.
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